AVM Biotechnology

Description: 

Stem Cell Technologies, Fully Human Biologics Manufacturing Cell Lines, Regenerative Medicine, CAR-T Immunotherapy & Cancer Treatment.

AVM Biotechnology has received FDA permission to proceed with clinical trials to evaluate its proprietary drug AVM0703 in the treatment of Acute Respiratory Distress Syndrome (ARDS) mediated by COVID-19 or Influenza patients. AVM0703 is a novel and proprietary formulation of high concentration of dexamethasone.

Location(s): 
Seattle WA
United States